In the randomized phase II AdvanTIG-203 trial, adding the anti-TIGIT antibody ociperlimab to tislelizumab did not improve response rates or survival in advanced esophageal squamous cell carcinoma. The study’s negative result reinforces the challenge of translating TIGIT co-inhibition into durable clinical benefit across unselected or difficult-to-treat solid tumor populations. While TIGIT remains a prominent immuno-oncology target, the trial outcome suggests the incremental clinical effect over PD-1 blockade was not clinically meaningful. For future combination planning, the result increases the importance of patient selection, biomarker strategy, and mechanism-specific endpoints rather than relying on regimen class effects alone.
Get the Daily Brief